Evidence map›Paper›PMID 35311592›Full record

Observational studyClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

Report of Low Incidence of Thrombosis with Early Prophylaxis in Hospitalized Patients with COVID-19 from Two Saudi Tertiary Centers.

Tarek Owaidah, Khalid Maghrabi, Feras Alfraih, Alfadil Haroon, Khawar Siddiqui, Randa Alnounou, Hadeel AlOtair, Fatmah S Alqahtany, Mohannad Maghrabi, Mustafa Owaidah and 1 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Early Prophylactic-Dose Thromboprophylaxis and 30-Day Mortality in Solid Tumor Patients Hospitalized for COVID-19: A Multicenter Retrospective Cohort Study.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Tarek OwaidahDepartment of Pathology and Laboratory Medicine, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.ORCID https://orcid.org/0000-0002-1856-2381
Khalid MaghrabiDepartment of Critical Care, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.
Feras AlfraihOncology Center, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.
Alfadil HaroonOncology Center, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.
Khawar SiddiquiDepartment of Pediatric Hematology Oncology, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.
Randa AlnounouDepartment of Pathology and Laboratory Medicine, 37852King Faisal Specialist Hospital and Research Centre, Riyadh, KSA.ORCID https://orcid.org/0000-0002-0134-5698
Hadeel AlOtairDepartment of Medicine, College of Medicine, 191082King Saud University, Riyadh, KSA.ORCID https://orcid.org/0000-0002-1385-6268
Fatmah S AlqahtanyDepartment of Pathology, Hematopathology Unit, College of Medicine, 191082King Saud University, King Saud University Medical City, Riyadh, Saudi Arabia.
Mohannad Maghrabi101686Alfaisal University, Riyadh, KSA.
Mustafa Owaidah101686Alfaisal University, Riyadh, KSA.
Khalid AlSalehDepartment of Oncology, College of Medicine, 191082King Saud University, Riyadh, Saudi Arabia.
King Faisal Specialist Hospital & Research Centre · SAAlfaisal University · SAKing Saud University · SAKing Saud Medical City · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThrombotic events can increase the COVID-19 associated disease mortality. The administration of prophylactic anticoagulants had been shown to decrease the incidence of thrombosis, mortality, and ICU admission rates in COVID-19 patients.

aimsThe present study investigates the rate of thrombosis with early anticoagulation prophylaxis, the various risk factors for thrombotic events, and the overall survival rate in hospitalized COVID-19 cases.

methodsIn this prospective observational study, 425 patients aged ≥14 years were included in the study who were hospitalized with COVID-19 related symptoms from March to October 2020 at two tertiary care hospitals in the Kingdom of Saudi Arabia. Venous thromboembolism (VTE) score was evaluated, and VTE prophylaxis was administered according to the hospital guidelines. Patients' demographics, comorbidities, disease presentation, and sequential hematological profiles were also recorded. Samples were collected at different time points to determine the hematological profiles.

resultsOut of 425 with positive COVID-19 subjects, eight (1.9%) patients developed thrombosis during admission, with pulmonary embolism being the most common type. VTE prophylaxis was administered to 394 (92.7%) patients. These anticoagulants included enoxaparin (86.3%), heparin (12.7%), warfarin (0.8%) and apixaban (0.3%). Comorbid conditions were recorded in 253 (59.5%) patients. ICU admission rate was 28% (n = 119), with a median time to transfer to ICU of 1 day (r: 0-33 days). A trend of high VTE score (5.0) with ICU admission and mortality (

conclusionWe are reporting a low incidence of thrombosis in COVID-19 patients. We have demonstrated that the early administration of prophylactic anticoagulants might reduce the risk of thrombotic events and the associated mortality. We observed a higher VTE score and thrombosis in patients admitted to the ICU.

Indexed as

COVID-19ThrombosisVenous ThromboembolismAdolescentHumansIncidenceSaudi ArabiaCOVID-19prophylaxisSaudithrombosis

Identifiers

PMID35311592
PMCPMC8938688
OpenAlexW4220818701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.